Development and Evaluation of an Ophthalmic Niosomal in situ gel loaded with Ripasudil

Open-angle glaucoma affects approximately 40 million people globally and poses a significant threat to vision. This study introduces a novel method for treating open-angle glaucoma using the medication Ripasudil, targeting the trabecular meshwork, a key factor in glaucoma progression. The delivery system, a niosomal in situ gel, is designed to be superior to traditional eye drop formulations.

The formulation has a particle size of 160 nm and an encapsulation efficiency of 88.5%, meeting therapeutic standards for glaucoma treatment. The optimization process involved a central composite design with 13 batches, focusing on optimizing drug concentration and surfactant ratio. Drug release kinetics showed a 98% release in 12hours, providing a sustained therapeutic impact.

This innovative treatment has the potential to significantly improve the lives of millions affected by glaucoma worldwide. The potential benefits include enhanced bioavailability of Ripasudil, improved patient adherence through sustained release, and increased treatment efficacy for glaucoma.